title: Evaluation of the effects of thyrotropin releasing hormone (TRH) therapy on regional cerebral blood flow in the cerebellar variant of multiple system atrophy using 3DSRT.
abstract: BACKGROUND
  Thyrotropin releasing hormone (TRH) improves cerebellar ataxia and cerebellar perfusion in patients with spinocerebellar degeneration. It is not known whether TRH therapy can improve the cerebellar regional cerebral blood flow (rCBF) or not in patients with cerebellar variant of multiple-system atrophy (MSA-C).
  
  
  METHODS
  Seven patients with MSA-C received TRH intravenously (2 mg/day) for 14 days. Clinical efficacy was assessed using the International Cooperative Ataxia Rating Scale (ICARS) and brain perfusion single photon emission-computed tomography was performed before and after therapy. The rCBF in each region of interest (ROI) was calculated using 3DSRT, a fully automated the ROI technique.
  
  
  RESULTS
  The ICARS scores slightly improved in 6 of the 7 patients after TRH therapy, but this was not statistically significant. After TRH therapy, the cerebellar rCBF reduced in the 6 of 7 patients and the mean rCBF in cerebellum also significantly decreased (P=0.029, paired t-test), whereas the rCBF in the precentral segment tend to increase (P=0.048, paired t-test).
  
  
  CONCLUSIONS
  TRH therapy may be less effective on cerebellar ataxia and cerebellar rCBF in MSA-C. The 3DSRT program may be useful for the evaluation of the efficacy of TRH therapy on cerebral blood flow.
authors.affiliation: Department of Internal Medicine III, Oita University, Faculty of Medicine, Oita, Japan. noriyuki@med.oita-u.ac.jp
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Kimura
authors.forename: Toshihide
authors.initials: T
authors.lastname: Kumamoto
authors.forename: Teruaki
authors.initials: T
authors.lastname: Masuda
authors.forename: Yuki
authors.initials: Y
authors.lastname: Nomura
authors.forename: Takuya
authors.initials: T
authors.lastname: Hanaoka
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Hazama
authors.forename: Toshio
authors.initials: T
authors.lastname: Okazaki
mesh_terms: D000368:Aged; D002526:Cerebellar Diseases / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D005260:Female; D006801:Humans; D021621:Imaging, Three-Dimensional; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D019578:Multiple System Atrophy / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D013973:Thyrotropin-Releasing Hormone / Q000008:administration & dosage / Q000627:therapeutic use*; D015899:Tomography, Emission-Computed, Single-Photon; D016896:Treatment Outcome
chemical_list: D013973:Thyrotropin-Releasing Hormone